|
|
|
| Analysis of prognostic factors in elderly patients with limited-stage small cell lung cancer |
| ZHAO Kai WANG Zhiwu YANG Junquan |
| The First Department of Chemoradiotherapy, Tangshan People′s Hospital, Hebei Province, Tangshan 063000, China |
|
|
|
Abstract Objective To explore the prognostic factors related to limited-stage small cell lung cancer in elderly patients, and to provide a reference for the selection of the best clinical treatment plan. Methods A retrospective analysis of 79 elderly patients with limited-stage small cell lung cancer treated in Tangshan People′s Hospital, Hebei Province from January 2010 to December 2016 was performed. The sex, age, Karnofsky performance status (KPS) score, smoking history, radiotherapy and chemotherapy mode, prophylactic cranial irradiation (PCI) situation, number of chemotherapy cycles and other information was collected. The study endpoint was overall survival. Univariate and multivariate survival analyses were used to identify independent prognostic factors. Results The median survival time of the 79 patients was 15.4 months, and the 2-year survival rate was 25.6%. The comparison of survival among different groups including gender, age, KPS score, smoking history, and treatment mode suggested that KPS score, PCI, and combination of radiotherapy and chemotherapy were prognostic factors (P ＜ 0.05), while age and number of chemotherapy cycles had marginal correlation with patient survival (0.05 ＜ P ＜ 0.10). The above factors were included in the multivariate analysis and the results suggested that KPS score, PCI, combined mode of radiotherapy and chemotherapy and the number of chemotherapy cycles were independent prognostic factors (P ＜ 0.05). Conclusion Good KPS, standard combination of radiotherapy and chemotherapy, adequate number of chemotherapy cycles, and performing PCI can provide survival benefits for elderly patients with limited-stage small cell lung cancer.
|
|
|
|
|
|
[1] Oronsky B，Reid TR，Oronsky A，et al. What′s new in sclc? A review [J]. Neoplasia，2017，19（10）：842-847.
[2] 肖家雯，孙素华.吉西他滨单药治疗老年晚期非小细胞肺癌的临床观察[J].中国医药导报，2009（13）：99-100.
[3] Roengvoraphoj O，Eze C，Niyazi M，et al. Prognostic role of patient gender in limited-disease small-cell lung cancer treated with chemoradiotherapy [J]. Strahlenther Onkol，2017，193（2）：150-155.
[4] Sun A，Durocher-Allen LD，Ellis PM，et al. Initial management of small-cell lung cancer （limited- and extensive-stage） and the role of thoracic radiotherapy and first-line chemotherapy：A systematic review [J]. Curr Oncol，2019，26（3）：e372-e384.
[5] Steffens CC，Elender C，Hutzschenreuter U，et al. Treatment and outcome of 432 patients with extensive-stage small cell lung cancer in first，second and third line - results from the prospective german tlk cohort study [J]. Lung Cancer，2019，130：216-225.
[6] Zimmerman S，Das A，Wang S，et al. 2017-2018 scientific advances in thoracic oncology：Small cell lung cancer [J]. J Thorac Oncol，2019，14（5）：768-783.
[7] Yang S，Zhang Z Wang Q. Emerging therapies for small cell lung cancer[J]. J Hematol Oncol，2019，12（1）：47.
[8] Povsic M，Enstone A，Wyn R，et al. Real-world effectiveness and tolerability of small-cell lung cancer （sclc） treatments： A systematic literature review（slr）[J]. PLoS One，2019，14（7）：e0 219 622.
[9] Eisenhauer E A，Therasse P，Bogaerts J，et al. New response evaluation criteria in solid tumours：revised RECIST guideline（version 1.1）[J]. Eur J Cancer，2009，45（2）：228-247.
[10] Schild SE，Bonner JA，Hillman S，et al. Results of a phase Ⅱ study of high-dose thoracic radiation therapy with concurrent cisplatin and etoposide in limited-stage small-cell lung cancer（ncctg 95-20-53）[J]. J Clin Oncol，2007，25（21）：3124-3129.
[11] Tomono H，Honda N，Dotsu Y，et al. Strategies to prevent brain metastasis [J]. Cancer Chemother Pharmacol，2019.
[12] Reymen B，Van Loon J，van Baardwijk A，et al. Total gross tumor volume is an independent prognostic factor in patients treated with selective nodal irradiation for stage Ⅰ to Ⅲ small cell lung cancer [J]. Int J Radiat Oncol Biol Phys，2013，85（5）：1319-1324.
[13] Péchoux CL，Sun A，Slotman BJ，et al. Prophylactic cranial irradiation for patients with lung cancer [J]. Lancet Oncol，2016，17（7）：e277-e293.
[14] Liu S，Guo H，Kong L，et al. The prognostic factors in the elderly patients with small cell lung cancer： A retrospective analysis from a single cancer institute [J]. Int J Clin Exp Pathol，2015，8（9）：11 033-11 041.
[15] Faivre-Finn C，Snee M，Ashcroft L，et al. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer（convert）：An open-label，phase 3，randomised，superiority trial [J]. Lancet Oncol，2017，18（8）：1116-1125.
[16] Wang S，Zimmermann S，Parikh K，et al. Current diagnosis and management of small-cell lung cancer [J]. Mayo Clin Proc，2019，94（8）：1599-1622.
[17] Levy A，Hendriks LEL，Le Péchoux C，et al. Current management of limited-stage sclc and convert trial impact： Results of the eortc lung cancer group survey [J]. Lung Cancer，2019，136：145-147.
[18] Ready NE，Pang HH，Gu L，et al. Chemotherapy with or without maintenance sunitinib for untreated extensive-stage small-cell lung cancer： A randomized，double-blind，placebo-controlled phase ii study-calgb 30504（alliance）[J]. J Clin Oncol，2015，33（15）：1660-1665.
[19] Hsu WH，Zhao X，Zhu J，et al. Checkpoint kinase 1 inhibition enhances cisplatin cytotoxicity and overcomes cisplatin resistance in sclc by promoting mitotic cell death [J]. J Thorac Oncol，2019，14（6）：1032-1045.
[20] Sharma P，Siefker-Radtke A，de Braud F，et al. Nivolumab alone and with ipilimumab in previously treated metastatic urothelial carcinoma： Checkmate 032 nivolumab 1 mg/kg plus ipilimumab 3 mg/kg expansion cohort results [J]. J Clin Oncol，2019，37（19）：1608-1616.
[21] Ott PA，Bang YJ，Piha-Paul SA，et al. T-cell-inflamed gene-expression profile，programmed death ligand 1 expression，and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 cancers：Keynote-028 [J]. J Clin Oncol，2019，37（4）：318-327. |
|
|
|
